Nicotinamide Deficiency in Primary Open-Angle Glaucoma
Authors:
- Judith Kouassi NzoughetJudith Kouassi Nzoughet
- Juan Manuel Chao de la BarcaJBJuan Manuel Chao de la Barca
- Khadidja GuehlouzKGKhadidja Guehlouz
- Stéphanie LeruezSLStéphanie Leruez
- Laurent CoulbaultLCLaurent Coulbault
- Stéphane AlloucheSAStéphane Allouche
- Cinzia BoccaCBCinzia Bocca
- Jeanne MullerJMJeanne Muller
- Philippe GohierPGPhilippe Gohier
- Dominique BonneauDBDominique Bonneau
Preprint
Abstract
Purpose: To investigate the plasma concentration of nicotinamide in primary open-angle glaucoma (POAG). Methods: Plasma of 34 POAG individuals were compared to that of 30 age-and sex-matched controls using a semi-quantitative method based on liquid chromatography coupled to high-resolution mass spectrometry. Subsequently, an independent quantitative method, based on liquid chromatography coupled to mass spectrometry, was used to assess nicotinamide concentration in the plasma from the same initial cohort and from a replicative cohort of 20 POAG individuals and 15 controls. Results: Using the semi-quantitative method, the plasma nicotinamide concentration was significantly lower in the initial cohort of POAG individuals compared to and further confirmed in the same cohort, using the targeted quantitative method, with mean concentrations of 0.14 µM (median: 0.12 µM; range: 0.06-0.28 µM) in the POAG group (−30 %; p = 0.022), and 0.19 µM (median: 0.18 µM; range: 0.08-0.47 µM) in the control group. The quantitative dosage also disclosed a significantly lower plasma nicotinamide concentration (−33 %; p = 0.011) in the replicative cohort with mean concentrations of 0.14 µM (median: 0.14 µM; range: 0.09-0.25 µM) in the POAG group, and 0.19 µM (median: 0.21 µM; range: 0.09-0.26 µM) in the control group. Conclusions: Glaucoma is associated with lower plasmatic nicotinamide levels, compared to controls, suggesting that nicotinamide supplementation might become a future therapeutic strategy. Further studies are needed, in larger cohorts, to confirm these preliminary findings.Keywords
All Related Versions
- Published version: Investigative Ophthalmology & Visual Science, 60 (7), 2509.
This publication has 22 references indexed in Scilit:
- Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in MiceCell Metabolism, 2016
- Nicotinamide mononucleotide inhibits post-ischemic NAD+ degradation and dramatically ameliorates brain damage following global cerebral ischemiaNeurobiology of Disease, 2016
- Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data AnalysisCurrent Protocols in Bioinformatics, 2016
- Glaucoma: Focus on mitochondria in relation to pathogenesis and neuroprotectionEuropean Journal of Pharmacology, 2016
- NAD + repletion improves mitochondrial and stem cell function and enhances life span in miceScience, 2016
- NAD + in aging, metabolism, and neurodegenerationScience, 2015
- Measurement of Systemic Mitochondrial Function in Advanced Primary Open-Angle Glaucoma and Leber Hereditary Optic NeuropathyPLOS ONE, 2015
- Metabolome-Wide Association Study of Primary Open Angle GlaucomaInvestigative Ophthalmology & Visual Science, 2015
- Impaired Complex-I-Linked Respiration and ATP Synthesis in Primary Open-Angle Glaucoma Patient LymphoblastsInvestigative Ophthalmology & Visual Science, 2012
- Primary open-angle glaucomaThe Lancet, 2004